{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T08:14:39Z","timestamp":1768896879824,"version":"3.49.0"},"reference-count":21,"publisher":"Cambridge University Press (CUP)","issue":"6","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":["cambridge.org"],"crossmark-restriction":true},"short-container-title":["Cardiol Young"],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec id=\"S1047951120004965_as1\"><jats:title>Introduction:<\/jats:title><jats:p>The prevalence of attention deficit\/hyperactivity disorder in the general population is common and is now diagnosed in 4%\u201312% of children. Children with CHD have been shown to be at increased risk for attention deficit\/hyperactivity disorder. Case reports have led to concern regarding the use of attention deficit\/hyperactivity disorder medications in children with underlying CHD. We hypothesised that medical therapy for patients with CHD and attention deficit\/hyperactivity disorder is safe.<\/jats:p><\/jats:sec><jats:sec id=\"S1047951120004965_as2\"><jats:title>Methods:<\/jats:title><jats:p>A single-centre, retrospective chart review was performed evaluating for adverse events in patients aged 4\u201321 years with CHD who received attention deficit\/hyperactivity disorder therapy over a 5-year span. Inclusion criteria were a diagnosis of CHD and concomitant medical therapy with amphetamines, methylphenidate, or atomoxetine. Patients with trivial or spontaneously resolved CHD were excluded from analysis.<\/jats:p><\/jats:sec><jats:sec id=\"S1047951120004965_as3\"><jats:title>Results:<\/jats:title><jats:p>In 831 patients with CHD who received stimulants with a mean age of 12.9 years, there was only one adverse cardiovascular event identified. Using sensitivity analysis, our median follow-up time was 686 days and a prevalence rate of 0.21% of adverse events. This episode consisted of increased frequency of supraventricular tachycardia in a patient who had this condition prior to initiation of medical therapy; the condition improved with discontinuation of attention deficit\/hyperactivity disorder therapy.<\/jats:p><\/jats:sec><jats:sec id=\"S1047951120004965_as4\"><jats:title>Conclusion:<\/jats:title><jats:p>The incidence of significant adverse cardiovascular events in our population was similar to the prevalence of supraventricular tachycardia in the general population. Our single-centre experience demonstrated no increased risk in adverse events related to medical therapy for children with attention deficit\/hyperactivity disorder and underlying CHD. Further population-based studies are indicated to validate these findings.<\/jats:p><\/jats:sec>","DOI":"10.1017\/s1047951120004965","type":"journal-article","created":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T08:54:51Z","timestamp":1612169691000},"page":"969-972","update-policy":"https:\/\/doi.org\/10.1017\/policypage","source":"Crossref","is-referenced-by-count":5,"title":["Treatment of attention deficit\/hyperactivity disorder in children with CHD"],"prefix":"10.1017","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6875-3621","authenticated-orcid":false,"given":"Alyson R.","family":"Pierick","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melodie","family":"Lynn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Courtney M.","family":"McCracken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew E.","family":"Oster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Glen J.","family":"Iannucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"56","published-online":{"date-parts":[[2021,2,1]]},"reference":[{"key":"S1047951120004965_ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2014.09.006"},{"key":"S1047951120004965_ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s00246-012-0162-6"},{"key":"S1047951120004965_ref19","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0b013e318265ee8a"},{"key":"S1047951120004965_ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2017.04.048"},{"key":"S1047951120004965_ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110212"},{"key":"S1047951120004965_ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2020.05.081"},{"key":"S1047951120004965_ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.athoracsur.2006.10.069"},{"key":"S1047951120004965_ref6","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2016-2241"},{"key":"S1047951120004965_ref16","unstructured":"16. FDA Drug Safety Communication. Safety Review Update of Medications used to treat Attention-Deficit\/Hyperactivity Disorder (ADHD) in adults, 2011. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-safety-review-update-medications-used-treat-attention-0#SAhttp:\/\/www.fda."},{"key":"S1047951120004965_ref5","doi-asserted-by":"publisher","DOI":"10.1542\/peds.105.5.1082"},{"key":"S1047951120004965_ref12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e4627"},{"key":"S1047951120004965_ref13","doi-asserted-by":"publisher","DOI":"10.1097\/MOP.0000000000000388"},{"key":"S1047951120004965_ref20","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)33004-1"},{"key":"S1047951120004965_ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2013.07.007"},{"key":"S1047951120004965_ref18","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-200212000-00001"},{"key":"S1047951120004965_ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtcvs.2004.08.013"},{"key":"S1047951120004965_ref17","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(97)00422-1"},{"key":"S1047951120004965_ref4","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2007-1066"},{"key":"S1047951120004965_ref11","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.107.189473"},{"key":"S1047951120004965_ref21","doi-asserted-by":"publisher","DOI":"10.1007\/s00246-013-0784-3"},{"key":"S1047951120004965_ref14","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-200105000-00011"}],"container-title":["Cardiology in the Young"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S1047951120004965","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,13]],"date-time":"2021-09-13T12:43:29Z","timestamp":1631537009000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S1047951120004965\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,1]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S1047951120004965"],"URL":"https:\/\/doi.org\/10.1017\/s1047951120004965","relation":{},"ISSN":["1047-9511","1467-1107"],"issn-type":[{"value":"1047-9511","type":"print"},{"value":"1467-1107","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,1]]},"assertion":[{"value":"\u00a9 The Author(s), 2021. Published by Cambridge University Press","name":"copyright","label":"Copyright","group":{"name":"copyright_and_licensing","label":"Copyright and Licensing"}}]}}